Background: Novel antipsychotics are superior to conventional antipsychotics,
as they significantly reduce both positive and negative symptoms of schizophrenia and
have lower risk of extra pyramidal syndrome (EPS). However, these drugs cause significant
metabolic side effects.
Objective: This study was carried out to assess the hospital prevalence of metabolic syndrome
(MetS) and metabolic profile related to use of oral risperidone which is one of the
most commonly used atypical antipsychotics.
Methods: A cross-sectional study was carried out on a period sample of 6 months, to study
the hospital prevalence and profile of MetS in adult patients on oral risperidone. Data was
collected from pharmacy dispensing records, patients’ case record files, and subsequently
patients were contacted telephonically and called to participate in this study.
Results: Hospital prevalence of MetS was found to be 12.1% (13 out of 107) by NCEP
ATP III criteria and 14.9% (16 out of 107) by IDF criteria in patients (aged 20 to 40 years)
on risperidone. Ninety one patients (85%) of the sample were found to be in Overweight
category and Central Obesity was found in 82(76.6%) patients. Twenty three (21.4%) of
the patients had increased triglyceride (TG) levels. Out of the 16 patients with MetS,
11(68.75%) of them had total duration of illness (TDI) of >4 years, 11(68.75%) were in
30-40 years age group, 13 (81.25%) of them had continued illness or they were in partial
remission, 11 (68.75%) of them were already exposed to any antipsychotics other than
risperidone, 6(37.5%) of them were having diabetes mellitus (DM) in one parents.
Conclusion: This study reported the hospital prevalence of MetS as 14.9% (IDF criteria) in
young adult patients on oral risperidone. The triglyceride levels and central obesity was also
found to be higher in patients, who otherwise had low prevalence of MetS.